title: Molecular precision chemotherapy: overcoming resistance to targeted therapies?
abstract: Cytotoxic drugs may have specific effects on oncogenes and their downstream targets. Increase of cancer cell sensitivity due to repression of an oncogene downstream target can be specifically addressed by combined precision chemotherapy, increasing the therapeutic index of chemotherapy and overcoming resistance to highly selective targeted therapies.
authors.affiliation: Author's Affiliation: Technische Universität München, München, Germany.
authors.forename: Stefan
authors.initials: S
authors.lastname: Burdach
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000494:pharmacology; D004249:DNA Damage / Q000187:drug effects*; D004149:Dioxoles / Q000494:pharmacology*; D005260:Female; D006801:Humans; D000077146:Irinotecan; D015514:Oncogene Proteins, Fusion / Q000037:antagonists & inhibitors*; D051789:Proto-Oncogene Protein c-fli-1 / Q000037:antagonists & inhibitors*; D034802:RNA-Binding Protein EWS / Q000037:antagonists & inhibitors*; D012512:Sarcoma, Ewing / Q000235:genetics* / Q000378:metabolism*; D044005:Tetrahydroisoquinolines / Q000494:pharmacology*; D000077606:Trabectedin
chemical_list: D000970:Antineoplastic Agents; D004149:Dioxoles; C106031:EWS-FLI fusion protein; D015514:Oncogene Proteins, Fusion; D051789:Proto-Oncogene Protein c-fli-1; D034802:RNA-Binding Protein EWS; D044005:Tetrahydroisoquinolines; D000077146:Irinotecan; D000077606:Trabectedin; D002166:Camptothecin